

— DOAC INTERFERENCE · LUPUS ANTICOAGULANT & THROMBOPHILIA TESTING

Read the plasma — *not the drug.*

Direct oral anticoagulants — **apixaban, rivaroxaban, edoxaban and dabigatran** — cause false-positive lupus anticoagulant results and skew clot-based thrombophilia assays whenever drug is present in the sample. Remove the drug from the plasma aliquot first, and the assay reflects the sample's true hemostasis. Two formats, one goal.

ACTIVATED-CHARCOAL TABLETS · 5-DIAGNOSTICS

DOAC-Remove

- Adsorbs **apixaban, rivaroxaban, edoxaban & dabigatran** from the plasma sample.
- Add one tablet, mix ~**10 min**, centrifuge — test the DOAC-free supernatant.
- Restores accurate **lupus anticoagulant, thrombophilia & routine coagulation** results — from a single DOAC-containing plasma sample.
- Three sizes: **20 / 50 / 250** tests (A5D-82410A / B / C).

A5D-82410A / B / C
FDA CLASS I · 510(K)-EXEMPT

\$80-556

FILTRATION CARTRIDGE · 5-DIAGNOSTICS

DP-Filter®

- Filters DOACs (**dabigatran, rivaroxaban, apixaban, edoxaban**) from plasma by non-covalent capture.
- Short incubation, then centrifuge through the filter — use the eluted plasma **directly or frozen**.
- A charcoal-free **filtration workflow** where a particle-free eluate is preferred.
- Single configuration (A5D-82412).

A5D-82412
RESEARCH USE ONLY

\$355

— WHERE DOACS DISTORT CLOT-BASED RESULTS

Lupus anticoagulant (dRVVT)

APTT-based LA

Antiphospholipid syndrome workup

Protein C / Protein S

Antithrombin

APC resistance

Thrombin time

Why remove the drug in vitro. DOACs produce false-positive lupus anticoagulant results and distort clot-based thrombophilia assays. Clearing the drug from the plasma aliquot before testing recovers the sample's true result, and is the approach reflected in current laboratory guidance on testing samples that contain anticoagulant.

SELECTED REFERENCES Favaloro EJ. Lupus anticoagulant testing during anticoagulation, including DOACs — *Res. Pract. Thromb. Haemost.* 2022;6(2):e12676. · Frans G, et al. Resolving DOAC interference on aPTT, PT and lupus anticoagulant testing using activated carbon — *J. Thromb. Haemost.* 2019;17:1354. · DOAC-Stop vs DOAC-Remove before thrombophilia/lupus testing — *Br. J. Biomed. Sci.* 2024;81:13359.

Regulatory: DOAC-Remove is an **FDA Class I, 510(k)-exempt** device (registered and listed) for the removal of direct oral anticoagulants from plasma prior to coagulation testing. **DP-Filter®** is **For Research Use Only — not for use in diagnostic procedures**. Removal performance depends on DOAC type and concentration; follow the use protocol supplied with each lot. Assay names indicate where DOACs are a recognized interference. Pricing shown is US list and subject to change. Therapeutic agents named are referenced as analytes / scientific context and are not Aniara products. © 2026 Aniara Diagnostica, Inc.